Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy.
Adverse effects
Bayesian network analysis
Fluoropyrimidine-based chemotherapy
Logistic modeling
Risk
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
19
12
2022
accepted:
23
04
2023
medline:
19
5
2023
pubmed:
10
5
2023
entrez:
10
5
2023
Statut:
ppublish
Résumé
Adverse effects following fluoropyrimidine-based chemotherapy regimens are common. However, there are no current accepted diagnostic markers for prediction prior to treatment, and the underlying mechanisms remain unclear. This study aimed to determine genetic and non-genetic predictors of adverse effects. Genomic DNA was analyzed for 25 single nucleotide polymorphisms (SNPs). Demographics, comorbidities, cancer and fluoropyrimidine-based chemotherapy regimen types, and adverse effect data were obtained from clinical records for 155 Australian White participants. Associations were determined by bivariate analysis, logistic regression modeling and Bayesian network analysis. Twelve different adverse effects were observed in the participants, the most common severe adverse effect was diarrhea (12.9%). Bivariate analysis revealed associations between all adverse effects except neutropenia, between genetic and non-genetic predictors, and between 8 genetic and 12 non-genetic predictors with more than 1 adverse effect. Logistic regression modeling of adverse effects revealed a greater/sole role for six genetic predictors in overall gastrointestinal toxicity, nausea and/or vomiting, constipation, and neutropenia, and for nine non-genetic predictors in diarrhea, mucositis, neuropathy, generalized pain, hand-foot syndrome, skin toxicity, cardiotoxicity and fatigue. The Bayesian network analysis revealed less directly associated predictors (one genetic and six non-genetic) with adverse effects and confirmed associations between six adverse effects, eight genetic predictors and nine non-genetic predictors. This study is the first to link both genetic and non-genetic predictors with adverse effects following fluoropyrimidine-based chemotherapy. Collectively, we report a wealth of information that warrants further investigation to elucidate the clinical significance, especially associations with genetic predictors and adverse effects.
Identifiants
pubmed: 37162533
doi: 10.1007/s00280-023-04538-3
pii: 10.1007/s00280-023-04538-3
pmc: PMC10191967
doi:
Substances chimiques
Fluorouracil
U3P01618RT
Antimetabolites
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-521Informations de copyright
© 2023. The Author(s).
Références
Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338. https://doi.org/10.1038/nrc1074
doi: 10.1038/nrc1074
pubmed: 12724731
Sonis ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4:277–284. https://doi.org/10.1038/nrc1318
doi: 10.1038/nrc1318
pubmed: 15057287
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB, Mucositis Study Section of the MASCC and the ISOO (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025. https://doi.org/10.1002/cncr.20162
doi: 10.1002/cncr.20162
pubmed: 15108222
Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N (2012) Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol 25:106–118
pubmed: 24713845
pmcid: 3959393
Garg MB, Lincz LF, Adler K, Scorgie FE, Ackland SP, Sakoff JA (2012) Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis. Br J Cancer 107:1525–1533. https://doi.org/10.1038/bjc.2012.421
doi: 10.1038/bjc.2012.421
pubmed: 22990653
pmcid: 3493765
Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y (2012) Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci 9:33–39. https://doi.org/10.7150/ijms.9.33
doi: 10.7150/ijms.9.33
pubmed: 22211087
US National Cancer Institute (2017) Common terminology criteria for adverse events. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf . Accessed Dec 2022
Barin-Le Guellec C, Lafay-Chebassier C, Ingrand I, Tournamille JF, Boudet A, Lanoue MC, Defossez G, Ingrand P, Perault-Pochat MC, Etienne-Grimaldi MC (2020) Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: a real-life evaluation in France. Eur J Cancer 124:37–46. https://doi.org/10.1016/j.ejca.2019.09.028
doi: 10.1016/j.ejca.2019.09.028
pubmed: 31715555
Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210–216. https://doi.org/10.1002/cpt.911
doi: 10.1002/cpt.911
pubmed: 29152729
Sakamoto K, Oka M, Yoshino S, Hazama S, Abe T, Okayama N, Hinoda Y (2006) Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy. Oncol Rep 16:381–387. https://doi.org/10.3892/or.16.2.381
doi: 10.3892/or.16.2.381
pubmed: 16820919
Coller JK, White IA, Logan RM, Tuke J, Richards AM, Mead KR, Karapetis CS, Bowen JM (2015) Predictive model for risk of severe gastrointestingal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Support Care Cancer 23:1233–1236. https://doi.org/10.1007/s00520-014-2481-z
doi: 10.1007/s00520-014-2481-z
pubmed: 25318697
Bogunia-Kubik K, Polak M, Lange A (2003) TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogenic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 32:617–622. https://doi.org/10.1038/sj.bmt.1704200
doi: 10.1038/sj.bmt.1704200
pubmed: 12953135
Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75:11–17. https://doi.org/10.1002/1097-0142(19950101)75:1%3c11::aid-cncr2820750104%3e3.0.co;2-n
doi: 10.1002/1097-0142(19950101)75:1<11::aid-cncr2820750104>3.0.co;2-n
pubmed: 7804963
Marques RP, Duarte GS, Sterrantino C, Pais HL, Quintela A, Martins AP, Costa J (2017) Triplet FOLFOXIRI versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 118:54–62. https://doi.org/10.1016/j.critrevonc.2017.08.006
doi: 10.1016/j.critrevonc.2017.08.006
pubmed: 28917269
R Core Team (2022) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
RStudio. https://www.rstudio.com/ . Accessed 30 Jan 2022
Scutari M (2010) Learning Bayesian Networks with the bnlearn R Package. J Stat Softw 35:1–22. https://doi.org/10.18637/jss.v035.i03
doi: 10.18637/jss.v035.i03
Hosmer Jnr DW, Lemeshow S, Sturdivant RX (2013) 5.2.4 area under the receiver operating characteristic curve. In: Applied logistic regression, 3rd edn. John Wiley & Sons, Incoporated, USA
Scutari M, Denis JB (2014) Bayesian networks: With examples in R. Chapman and Hall/CRC, United Kingdom
doi: 10.1201/b17065
Aprile G, Ramoni M, Keefe D, Sonis S (2008) Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 112:284–292. https://doi.org/10.1002/cncr.23182
doi: 10.1002/cncr.23182
pubmed: 18041060
Lees JG, Makker PG, Tonkin RS, Abdulla M, Park SB, Goldstein D, Moalem-Taylor G (2017) Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur J Cancer 73:22–29. https://doi.org/10.1016/j.ejca.2016.12.006
doi: 10.1016/j.ejca.2016.12.006
pubmed: 28104535
Zimmerman L, Pozehl B, Vuckovic K, Barnason S, Schulz P, Seo Y, Ryan CJ, Zerwic JJ, DeVon HA (2016) Selecting symptom instruments for cardiovascular populations. Heart Lung 45:475–496. https://doi.org/10.1016/j.hrtlng.2016.08.012
doi: 10.1016/j.hrtlng.2016.08.012
pubmed: 27686695
Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8:93–97. https://doi.org/10.1093/hmg/8.1.93
doi: 10.1093/hmg/8.1.93
pubmed: 9887336
Shah R, Rahaman B, Hurley CK, Posch PE (2006) Allelic diversity in the TGFB1 regulatory region: characterization of novel functional single nucleotide polymorphisms. Hum Genet 119:61–74. https://doi.org/10.1007/s00439-005-0112-y
doi: 10.1007/s00439-005-0112-y
pubmed: 16369764
Smith AJP, Humphries SE (2009) Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 20:43–59. https://doi.org/10.1016/j.cytogfr.2008.11.006
doi: 10.1016/j.cytogfr.2008.11.006
pubmed: 19038572
Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, van der Meer JW, Netea MG (2008) Functional consequences of toll-like receptor 4 polymorphisms. Mol Med 14:346–352. https://doi.org/10.2119/2007-00135.Ferwerda
doi: 10.2119/2007-00135.Ferwerda
pubmed: 18231573
pmcid: 2215765
Wong DVT, Holanda RBF, Cajado AG, Bandeira AM, Pereira JFB, Amorim JO, Torres CS, Ferreira LMM, Lopes MHS, Oliveira RTG, Pereira AF, Sant’Ana RO, Arruda LM, Ribeiro-Júnior HL, Pinheiro RF, Almeida PRC, Carvalho RF, Chaves FF, Rocha-Filho DR, Cunha FQ, Lima-Júnior RCP (2021) TLR4 deficiency upregulates TLR9 expression and enhances irinotecan-related intestinal mucositis and late-onset diarrhoea. Br J Pharmacol 178:4193–4209. https://doi.org/10.1111/bph.15609
doi: 10.1111/bph.15609
pubmed: 34216140
Sonis ST (2002) The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13:380–389. https://doi.org/10.1177/154411130201300502
doi: 10.1177/154411130201300502
pubmed: 12393757
Sonis ST (2004) A biological approach to mucositis. J Support Oncol 2:21–32 (discussion 35–26)
pubmed: 15330370
Božina N, Bilić I, Ganoci L, Šimičević L, Pleština S, Lešnjaković L, Trkulja V (2022) DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. Br J Clin Pharmacol 88:2190–2202. https://doi.org/10.1111/bcp.15144
doi: 10.1111/bcp.15144
pubmed: 34780066
Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257–269. https://doi.org/10.1016/s0092-8674(03)00035-7
doi: 10.1016/s0092-8674(03)00035-7
pubmed: 12553913
Chen F, Yu Y, Wang P, Dong Y, Wang T, Zuo X, Li Y (2014) Brain-derived neurotrophic factor accelerates gut motility in slow-transit constipation. Acta Physiol (Oxf) 212:226–238. https://doi.org/10.1111/apha.12374
doi: 10.1111/apha.12374
pubmed: 25164090
Sharma GP, Frei AC, Narayanan J, Gasperetti T, Veley D, Amjad A, Albano K, Fish BL, Himburg HA (2021) Brain-derived neurotrophic factor promotes immune reconstitution following radiation injury via activation of bone marrow mesenchymal stem cells. PLoS ONE 16:e0259042. https://doi.org/10.1371/journal.pone.0259042
doi: 10.1371/journal.pone.0259042
pubmed: 34695155
pmcid: 8544859
Barbosa SJA, Oliveira MMB, Ribeiro SB, de Medeiros CACX, Lima MLS, Guerra GCB, de Araújo Jr RF, de Sousa Jr FC, Martins AA, Paiva DFF, Andrade RVS, Rebouças CSM, Brito GAC, Leitâo RFC, de Araújo AA (2022) The beneficial effects of Lacticaseibacillus casei on the small intestine and colon of Swiss mice against the deleterious effects of 5-fluorouracil. Front Immunol 13:954885. https://doi.org/10.3389/fimmu.2022.954885
doi: 10.3389/fimmu.2022.954885
pubmed: 36341441
pmcid: 9635922
Martinon F, Tschopp J (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14:10–22. https://doi.org/10.1038/sj.cdd.4402038
doi: 10.1038/sj.cdd.4402038
pubmed: 16977329
Desai CK, Iyer G, Panchal J, Shah S, Dikshit RK (2011) An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res 2:129–136. https://doi.org/10.4103/2229-3485.86883
doi: 10.4103/2229-3485.86883
pubmed: 22145123
pmcid: 3227330
Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915. https://doi.org/10.1200/JCO.2014.57.9334
doi: 10.1200/JCO.2014.57.9334
pubmed: 25624439
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J (2019) Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 20:1451. https://doi.org/10.3390/ijms20061451
doi: 10.3390/ijms20061451
pubmed: 30909387
pmcid: 6471666
Peppone LJ, Mustian KM, Morrow GR, Dozier AM, Ossip DJ, Janelsins MC, Sprod LK, McIntosh S (2011) The effect of cigarette smoking on cancer treatment-related side effects. Oncologist 16:1784–1792. https://doi.org/10.1634/theoncologist.2011-0169
doi: 10.1634/theoncologist.2011-0169
pubmed: 22135122
pmcid: 3248778
McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K (2016) Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol 7:414. https://doi.org/10.3389/fphar.2016.00414
doi: 10.3389/fphar.2016.00414
pubmed: 27857691
pmcid: 5093116
Nagore E, Insa A, Sanmartín O (2000) Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol 1:225–234. https://doi.org/10.2165/00128071-200001040-00004
doi: 10.2165/00128071-200001040-00004
pubmed: 11702367
Weyrich P, Staiger H, Stančáková A, Machicao F, Machann J, Schick F, Stefan N, Kuusisto J, Laakso M, Schäfer S, Fritsche A, Häring HU (2010) The D299G/T399I Toll-like receptor 4 variant associates with body and liver fat: results from the TULIP and METSIM studies. PLoS ONE 5:e13980. https://doi.org/10.1371/journal.pone.0013980
doi: 10.1371/journal.pone.0013980
pubmed: 21125016
pmcid: 2981584
Somogyi AA, Sia AT, Tan EC, Coller JK, Hutchinson MR, Barratt DT (2016) Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain 157:2458–2466. https://doi.org/10.1097/j.pain.0000000000000661
doi: 10.1097/j.pain.0000000000000661
pubmed: 27649267
Rha SY, Park M, Lee J (2019) Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy. Support Care Cancer 27:1687–1695. https://doi.org/10.1007/s00520-018-4413-9
doi: 10.1007/s00520-018-4413-9
pubmed: 30120557
Han CJ, Reding K, Cooper BA, Paul SM, Conley YP, Hammer M, Kober KM, Levine JD, Miaskowski C (2019) Stability of symptom clusters in patients with gastrointestinal cancers receiving chemotherapy. J Pain Symptom Manag 58:989-1001.e1010. https://doi.org/10.1016/j.jpainsymman.2019.07.029
doi: 10.1016/j.jpainsymman.2019.07.029
Rha SY, Lee J (2021) Stable symptom clusters and evolving symptom networks in relation to chemotherapy cycles. J Pain Symptom Manag 61:544–554. https://doi.org/10.1016/j.jpainsymman.2020.08.008
doi: 10.1016/j.jpainsymman.2020.08.008